Tuesday, April 28, 2020 Daily Archives

Sanofi sets out COVID-19 vaccine scale-out plans for protein and mRNA candidates

by

There are 94 COVID-19 vaccines in development but almost no capacity to produce them at meaningful scale says Sanofi, which is aiming to go from 100 million doses of a recombinant protein candidate to a billion in 12 months. Industry’s response to coronavirus (SARS-CoV-2) has been, to use the word of the moment, unprecedented. Scores of COVID-19 vaccines are in various stages of development. Sanofi is involved in two vaccine programs, representing a “huge opportunity for our organization,†CEO Paul…

April 28, 2020

Fujifilm licenses AAV vector tech to speed gene therapy production

by

CDMO Fujifilm Diosynth Biotechnologies (FDB) says partnering with OXGENE could reduce the lead time of its customers’ gene therapy projects by up to 25%. The technology, licensed from UK-based OXGENE for an undisclosed fee, consists of Helper, Rep/Cap and Gene of Interest plasmids, used in combination with a clonal suspension a HEK293 cell line. The AAV system is expected to reduce the length of the supply chain gene therapy customers, according to contract development and manufacturing organization (CDMO) FDB, with…

April 28, 2020